Peter Reichardt

34.5k total citations · 10 hit papers
354 papers, 15.6k citations indexed

About

Peter Reichardt is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Oncology. According to data from OpenAlex, Peter Reichardt has authored 354 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 260 papers in Pulmonary and Respiratory Medicine, 146 papers in Gastroenterology and 121 papers in Oncology. Recurrent topics in Peter Reichardt's work include Sarcoma Diagnosis and Treatment (151 papers), Gastrointestinal Tumor Research and Treatment (146 papers) and Gastric Cancer Management and Outcomes (124 papers). Peter Reichardt is often cited by papers focused on Sarcoma Diagnosis and Treatment (151 papers), Gastrointestinal Tumor Research and Treatment (146 papers) and Gastric Cancer Management and Outcomes (124 papers). Peter Reichardt collaborates with scholars based in Germany, United States and France. Peter Reichardt's co-authors include Jean‐Yves Blay, Paolo G. Casali, Jaap Verweij, Peter Hohenberger, Daniel Pink, M. van Glabbeke, Pancras C.W. Hogendoorn, Ian Judson, Rolf D. Issels and John Zalcberg and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Reichardt

339 papers receiving 15.2k citations

Hit Papers

Progression-free survival in gastrointestinal stromal tum... 1996 2026 2006 2016 2004 2003 2005 1996 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    2004 1.3k citations Paolo G. Casali, Peter Reichardt et al. profile →
  2. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
    2003 649 citations Leo Kager, Peter Reichardt et al. Journal of Clinical Oncology profile →
  3. Consensus meeting for the management of gastrointestinal stromal tumors
 Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
    2005 561 citations Jean‐Yves Blay, Paolo G. Casali et al. Annals of Oncology profile →
  4. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
    1996 508 citations Peter Reichardt et al. profile →
  5. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
    2010 507 citations Florian Lordick, Peter Reichardt et al. Journal of Clinical Oncology profile →
  6. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
    2010 486 citations Rolf D. Issels, Lars H. Lindner et al. profile →
  7. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
    2013 430 citations Jean‐Yves Blay, Peter Reichardt et al. profile →
  8. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    2011 429 citations Peter Thuss‐Patience, Axel Hinke et al. European Journal of Cancer profile →
  9. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
    2012 383 citations Peter Reichardt, Peter Hohenberger et al. profile →
  10. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
    2020 251 citations Jean‐Yves Blay, Sebastian Bauer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Reichardt Germany 61 9.7k 5.7k 4.2k 4.2k 2.1k 354 15.6k
Peter Hohenberger Germany 57 9.0k 0.9× 4.1k 0.7× 3.8k 0.9× 5.1k 1.2× 1.7k 0.8× 369 13.8k
Margaret von Mehren United States 55 10.7k 1.1× 9.3k 1.6× 5.0k 1.2× 4.1k 1.0× 1.0k 0.5× 282 16.3k
Brian P. Rubin United States 67 11.1k 1.1× 7.3k 1.3× 5.2k 1.2× 4.2k 1.0× 3.7k 1.8× 275 19.2k
Suzanne George United States 55 6.8k 0.7× 4.0k 0.7× 2.1k 0.5× 3.7k 0.9× 863 0.4× 257 11.7k
Chandrajit P. Raut United States 52 6.0k 0.6× 2.3k 0.4× 3.3k 0.8× 4.3k 1.0× 1.1k 0.5× 202 9.5k
Angelo Paolo Dei Tos Italy 67 10.9k 1.1× 2.5k 0.4× 3.4k 0.8× 6.1k 1.4× 4.5k 2.2× 438 17.0k
John R. Goldblum United States 79 12.4k 1.3× 4.1k 0.7× 9.7k 2.3× 5.7k 1.3× 4.7k 2.3× 362 22.7k
Abbas Agaimy Germany 56 4.3k 0.4× 2.1k 0.4× 5.1k 1.2× 4.1k 1.0× 2.1k 1.0× 611 12.8k
Robert G. Maki United States 88 18.3k 1.9× 8.0k 1.4× 5.3k 1.2× 9.7k 2.3× 3.7k 1.8× 377 26.3k
Eva Wardelmann Germany 51 4.1k 0.4× 2.8k 0.5× 2.1k 0.5× 2.1k 0.5× 856 0.4× 292 10.5k

Countries citing papers authored by Peter Reichardt

Since Specialization
Citations

This map shows the geographic impact of Peter Reichardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Reichardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Reichardt more than expected).

Fields of papers citing papers by Peter Reichardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Reichardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Reichardt. The network helps show where Peter Reichardt may publish in the future.

Co-authorship network of co-authors of Peter Reichardt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Reichardt. A scholar is included among the top collaborators of Peter Reichardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Reichardt. Peter Reichardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Andreou, Dimosthenis, Claudia Blattmann, Godehard Friedel, et al.. (2026). Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS). Journal of Cancer Research and Clinical Oncology. 152(1). 40–40.
2.
Falkenhorst, Johanna, Philipp Ivanyi, Rainer Hamacher, et al.. (2025). Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial). Clinical Cancer Research. 31(19). 4059–4069.
3.
Schöffski, Patrick, Patricia LoRusso, Nobuyuki Yamamoto, et al.. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open. 9. 102446–102446. 3 indexed citations
4.
Kasper, Bernd, Noah Federman, Peter Reichardt, et al.. (2024). Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.. Journal of Clinical Oncology. 42(16_suppl). 11558–11558. 3 indexed citations
5.
Reichardt, Peter, Philipp Harter, Stefan Kommoss, et al.. (2023). Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).. Journal of Clinical Oncology. 41(16_suppl). e17632–e17632.
6.
Bielack, Stefan, Leo Kager, Thomas Kühne, et al.. (2023). Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS). Cancers. 15(5). 1520–1520. 7 indexed citations
7.
Reichardt, Peter, et al.. (2023). Gastrointestinale Stromatumoren des Rektums. coloproctology. 46(1). 22–29.
8.
Joensuu, Heikki, Eva Wardelmann, Mikael Eriksson, et al.. (2023). KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial. Clinical Cancer Research. 29(17). 3313–3319. 13 indexed citations
9.
Oberacker, Eva, Stefanie Corradini, Franziska Eckert, et al.. (2023). Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. International Journal of Hyperthermia. 40(1). 2236337–2236337. 4 indexed citations
10.
11.
Ihle, Michaela A., Sebastian Huss, Wolfgang Hartmann, et al.. (2018). Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. PLoS ONE. 13(2). e0193048–e0193048. 18 indexed citations
12.
Kasper, Bernd, Viktor Gruenwald, Peter Reichardt, et al.. (2017). Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer. 76. 60–67. 83 indexed citations
13.
Kasper, Bernd, Peter Reichardt, Markus K. Schuler, & Peter Hohenberger. (2017). Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13). Annals of Oncology. 28. v538–v538. 2 indexed citations
14.
15.
Joensuu, Heikki, Mikael Eriksson, Kirsten Sundby Hall, et al.. (2015). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology. 34(3). 244–250. 149 indexed citations
16.
Kappeler, Christian, Peter Reichardt, Yoon‐Koo Kang, et al.. (2015). O-016 Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial. Annals of Oncology. 26. iv114–iv114. 2 indexed citations
17.
Bauer, Sebastian, Thomas Mühlenberg, Florian Grabellus, et al.. (2014). Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer. 110(5). 1155–1162. 39 indexed citations
18.
Bauer, Sebastian, Jean‐Yves Blay, Paolo G. Casali, et al.. (2013). Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST). European Journal of Cancer. 49. 1 indexed citations
19.
Hook, Jennifer, Gordana Jovic, Neyssa Marina, et al.. (2012). Lack of trial participation and lack of centralization for young adults with osteosarcoma: Experience from the European and American Osteosarcoma Study, EURAMOS-1. UCL Discovery (University College London). 1 indexed citations
20.
Reichardt, Peter, Jean‐Yves Blay, & Margaret von Mehren. (2010). Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 10(2). 221–232. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Hohenberger Breakdown of academic impact, for papers by Margaret von Mehren Breakdown of academic impact, for papers by Brian P. Rubin Breakdown of academic impact, for papers by Suzanne George Breakdown of academic impact, for papers by Chandrajit P. Raut Breakdown of academic impact, for papers by Angelo Paolo Dei Tos Breakdown of academic impact, for papers by John R. Goldblum Breakdown of academic impact, for papers by Abbas Agaimy Breakdown of academic impact, for papers by Robert G. Maki Breakdown of academic impact, for papers by Eva Wardelmann
Rankless by CCL
2026